GlassScriptPhysician profile
Nancy M Hsiao
NPI 1497807622
$4,134.30
in general payments reported to CMS, 2019-2025
26 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2022: $690 · 2023: $519 · 2024: $1,190 · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,223 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,223.44 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $769.63 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $389.27 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $357.92 | 2022-2025 | Jardiance, Kisunla, Zepbound |
| Amgen INC. | $313.23 | 2022-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $256.19 | 2023-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Astellas Pharma US INC | $233.40 | 2023-2025 | Veozah |
| Pfizer INC. | $228.37 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $219.30 | 2022-2024 | |
| Abbvie INC. | $204.00 | 2023-2025 | |
| Abbott Laboratories | $175.31 | 2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $160.33 | 2022-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $135.70 | 2019 | |
| Aimmune Therapeutics, INC. | $91.67 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.68 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $75.83 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $70.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $69.52 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.41 | 2024-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $50.91 | 2025 | Zoryve |
| Radius Health, INC. | $45.43 | 2025 | Tymlos |
| Csl Behring | $43.30 | 2024 | Haegarda |
| Lundbeck LLC | $26.29 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $22.85 | 2023 | |
| Esperion Therapeutics, INC. | $20.52 | 2025 | Nexletol |
| Intra-Sana Laboratories | $19.42 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Dexcom, INC. | $19.38 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Hsiao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.